Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2
Abstract
There are similar challenges in developing a product designed to treat patients with a rare disease and drugs to treat critically ill neonates and infants. Part of the challenge in developing such products as well as identifying the optimal dosing regimen for the treatment of young children arises from the complex interrelationship between developmental changes and changes in biomarkers responsive to drug therapy. These difficulties are further compounded by our lack of understanding of the key physiological factors that cause the differences in clinical responses between adults and neonates and infants. Regulatory efforts have succeeded in overcoming these challenges in many areas of pediatric and orphan drug development. Strategic applications of biomarkers and surrogate endpoints for the development and approval of a product used to treat an orphan disease will be highlighted with examples of approved products. Continued efforts are still needed to fill in our knowledge gap and to strategically link biomarkers and surrogate endpoints to clinical responses for rare diseases and diseases affecting neonates and infants.
Authors and Affiliations
Jane P. F. Bai, Jeffrey S. Barrett, Gibert J. Burckart, Bernd Meibohm, Hari Cheryl Sachs, Lynne Yao
Keywords
Related Articles
- EP ID EP681114
- DOI 10.1208/s12248-013-9452-z
- Views 62
- Downloads 0
Pain Assessment in Human Fetus and Infants
In humans, painful stimuli can arrive to the brain at 20–22 weeks of gestation. Therefore several researchers have devoted their efforts to study fetal analgesia during prenatal surgery, and during painfu...
Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles
This article describes the production and characterization of cationic submicron particles constituted with Eudragit RS 100, plus different cationic surfactants, such as dioctadecyl-dimethyl-ammonium bromide (DDAB18) and...
Microdialysis as a tool in local pharmacodynamics
In many cases the clinical outcome of therapy needs to be determined by the drug concentration in the tissue compartment in which the pharmacological effect occurs rather than in the plasma. Microdialysis is an in vivo t...
Spray-Dried Microparticles Containing Polymeric Micelles Encapsulating Hematoporphyrin
The purpose of this study was to examine the properties of a new pulmonary delivery platform of microparticles containing micelles in which a therapeutic photosensitizing drug, hematoporphyrin (Hp), was encapsulated. Dif...
Erratum to: A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion
The online version of the original article can be found at 10.1208/s12248-015-9753-5.